Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus toripalimab). The median progression-free survival (PFS) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, He, Ming-Ming, Yao, Yi-Chen, Zhao, Xia, Wang, Zhi-Qiang, Jin, Ying, Luo, Hui-Yan, Li, Ji-Bin, Wang, Feng-Hua, Qiu, Miao-Zhen, Lv, Zhi-Da, Wang, De-Shen, Li, Yu-Hong, Zhang, Dong-Sheng, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484502/
https://www.ncbi.nlm.nih.gov/pubmed/34622226
http://dx.doi.org/10.1016/j.xcrm.2021.100383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484502/
https://www.ncbi.nlm.nih.gov/pubmed/34622226
http://dx.doi.org/10.1016/j.xcrm.2021.100383

Ejemplares similares